Eptinezumab Anti-CGRP monoclonal antibody Treatment of migraine

摘要

Eptinezumab (ALD-403) is a genetically engineered, humanized, desialylated anti-calcitonin gene-related peptide (CGRP) IgG1 monoclonal antibody that selectively binds to both a and beta forms of human CGRP, which is a promising therapeutic target for migraine. Pharmacokinetic data indicated that monthly dosing of an intravenous eptinezumab infusion could maintain bioactive levels and blood concentration for a long time. Phase I and II studies evaluating the safety and efficacy of eptinezumab in episodic and chronic migraine were completed with encouraging results, and there are currently three large phase III studies ongoing. This review summarizes the clinical trials already conducted or ongoing and the initial findings regarding the safety and efficacy of eptinezumab for the treatment of migraine.